Physician

Fuad Aleskerov, M.D.

According to 2025 Medicare claims, Fuad Aleskerov, M.D. (NPI: 1730565490) practices pulmonary disease in the Burlington, NC market, with the plurality of this provider's patient population coming from Alamance, NC. This provider's primary affiliated billing organization is DUKE HEALTH INTEGRATED PRACTICE, INC. (NPI: 1205553369; TIN: 862109896) and primary practice location at 27215-8700. Aleskerov is affiliated with the Duke Connected Care, LLC (ACO ID: A2419) and Triad HealthCare Network, LLC. (ACO ID: D0209), participating under both the MSSP and REACH models.

Aleskerov's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 294 traditional Medicare patients, billed 1,913 HCPCS/CPT codes, and received $113,658 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,428 prescription claims across 686 beneficiaries totaling $1,836,641 in drug costs, led by Dupixent Pen (Dupilumab). DME data shows 1,117 claims. Open Payments data shows 29 records totaling $37,813. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $43,399 and ending at $113,658. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $341 to $1,836,641. For DME billing, reported payments rose steadily, from $3,037 to $62,204.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	168	496	$43,399
2016	666	1,839	$148,647
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	31	118	$6,178
2020	315	1,700	$156,407
2021	357	1,887	$176,806
2022	325	1,916	$147,940
2023	306	1,615	$120,310
2024	294	1,913	$113,658

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	12	$341
2016	96	210	$12,435
2017	N/R	39	$9,018
2018	16	118	$31,721
2019	39	157	$39,616
2020	253	1,265	$334,251
2021	458	2,530	$907,406
2022	577	4,122	$1,724,804
2023	683	4,648	$1,349,193
2024	686	4,428	$1,836,641

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	53	$2,403
2017	N/R	N/R	N/R
2018	N/R	14	$409
2019	N/R	N/R	N/R
2020	220	754	$60,540
2021	263	1,356	$109,258
2022	167	1,048	$59,742
2023	308	1,128	$62,654
2024	273	1,117	$101,098

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	181	323	$125
94729	Test to examine how well the lungs exchange gases	118	138	$40
94726	Test to determine lung volumes using sensors	118	138	$40
94010	Test to measure expiratory airflow and volume	148	188	$19
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	175	268	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Pen	Dupilumab	172	4,690	$665,061
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	551	21,930	$464,671
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	129	5,730	$117,971
Combivent Respimat	Ipratropium/Albuterol Sulfate	119	4,416	$77,883
Nucala	Mepolizumab	15	420	$52,935

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7699	Noc drugs, inhalation solution administered through dme	N	N/R	11	$26,205
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	17	$17,170
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	22	$16,679
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	25	178	$12,663
E1392	Portable oxygen concentrator, rental	Y	21	146	$4,646

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$37,813	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Fuad Aleskerov, M.D.?

Tedicare shows public-source Medicare data for Fuad Aleskerov, M.D. (NPI 1730565490), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Fuad Aleskerov, M.D. have ACO affiliation data?

Fuad Aleskerov, M.D. is shown with ACO affiliation data for Duke Connected Care, LLC (MSSP, ACO ID A2419) and Triad HealthCare Network, LLC. (REACH, ACO ID D0209).

What billing organization is linked to Fuad Aleskerov, M.D.?

Fuad Aleskerov, M.D. is linked to DUKE HEALTH INTEGRATED PRACTICE, INC. (billing NPI 1205553369) in the available physician profile data.

Does Fuad Aleskerov, M.D. have Open Payments data?

Fuad Aleskerov, M.D. has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.